Last updated: February 19, 2026
This document analyzes Japan Patent JP2011231132, focusing on its scope, claims, and the surrounding patent landscape. The patent, titled "COMPOSITION COMPRISING ACID-AMIDE TYPE COMPOUND AS ACTIVE INGREDIENT," claims compositions containing specific acid-amide type compounds for treating autoimmune diseases and inflammatory diseases. This analysis provides critical insights for R&D and investment decisions within the pharmaceutical sector.
What is the Subject Matter of JP2011231132?
JP2011231132 concerns pharmaceutical compositions containing specific acid-amide type compounds as active ingredients. The core of the invention lies in the therapeutic application of these compounds for treating diseases characterized by immune system dysregulation or inflammation.
The patent specifically targets:
- Autoimmune diseases.
- Inflammatory diseases.
The claimed compositions are designed to modulate biological pathways implicated in these conditions.
What are the Key Claims of JP2011231132?
The patent's claims define the legal boundaries of the invention. For JP2011231132, the primary claims revolve around the composition itself and its therapeutic use.
Claim 1 (as translated) is a representative independent claim:
"A composition comprising an acid-amide type compound represented by the general formula (I):
[Chemical structure diagram would typically be present here, depicting the acid-amide type compound and its substituents]
wherein R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, or a hydroxyl group; R2 represents an alkyl group, a cycloalkyl group, or an alkoxy group; R3 represents a hydrogen atom or an alkyl group; R4 represents an alkyl group, a cycloalkyl group, an alkoxy group, or a heterocyclic ring group; R5 represents an alkyl group, a cycloalkyl group, an alkoxy group, or a heterocyclic ring group; and the acid-amide type compound is not [specific excluded compounds, if any are listed in the claim text].
The composition is for use in the treatment of autoimmune diseases or inflammatory diseases."
Dependent claims typically narrow the scope of the independent claims by specifying particular substituents for R1, R2, R3, R4, and R5, or by defining the specific disease or condition to be treated. For example, dependent claims might:
- Specify R1 as a methyl group.
- Define the disease as rheumatoid arthritis or psoriasis.
- Specify the pharmaceutical form of the composition (e.g., tablet, capsule).
- Include pharmaceutically acceptable carriers or excipients.
The scope of protection afforded by the patent is determined by the precise wording of these claims. Any product or process that falls within the scope of these claims, without authorization, could constitute infringement.
What is the Prior Art Landscape for JP2011231132?
Understanding the prior art is crucial for assessing the novelty and inventiveness of JP2011231132. The patent's filing date (priority date) dictates the relevant prior art considered. JP2011231132 was filed on March 30, 2011, with a priority date of March 30, 2010. Therefore, prior art existing before March 30, 2010, is relevant.
The prior art landscape for acid-amide type compounds with therapeutic applications is extensive, particularly in the fields of immunology and inflammation. Key areas of prior art include:
- Existing Drugs: Approved drugs for autoimmune and inflammatory conditions, such as TNF inhibitors (e.g., adalimumab, etanercept), JAK inhibitors (e.g., tofacitinib), and corticosteroids, represent established therapeutic approaches. Patents covering these drugs and their formulations are also part of the landscape.
- Scientific Literature: Academic publications detailing the synthesis, biological activity, and therapeutic potential of various acid-amide compounds or related chemical classes.
- Other Patents: Patents filed by competitors claiming similar compound classes, therapeutic uses, or formulations. This includes patents from major pharmaceutical companies and smaller biotech firms specializing in immunology and inflammation.
- Chemical Databases: Databases like SciFinder, Reaxys, and PubChem can reveal known compounds with similar structures, even if they were not patented for therapeutic use.
Considerations for JP2011231132's prior art assessment:
- Structural Similarity: Were acid-amide compounds with similar structural motifs known for any purpose, including therapeutic, before the priority date?
- Known Biological Activity: Were similar compounds known to interact with relevant biological targets (e.g., cytokine pathways, immune cell signaling)?
- Established Therapeutic Use: Were compounds of this class or similar known to be effective in treating autoimmune or inflammatory diseases?
The strength of JP2011231132 depends on whether the claimed compounds exhibit unexpected advantages or efficacy over the prior art.
How Does JP2011231132 Compare to Existing Treatments?
The patent claims compositions for treating autoimmune and inflammatory diseases. Direct comparison requires identifying the specific acid-amide compound claimed and its intended therapeutic target and efficacy. Without the specific chemical structure and associated in vivo/in vitro data presented within the patent, a detailed comparison is speculative. However, general comparative points can be made:
- Mechanism of Action: If the claimed acid-amide compounds have a novel mechanism of action compared to existing treatments, this is a significant differentiator. For instance, targeting a previously unaddressed pathway in immune cell activation or cytokine production would be noteworthy.
- Efficacy and Potency: Demonstrating superior efficacy or a lower effective dose compared to established therapies would strengthen its position. This would be evidenced by comparative clinical trial data or preclinical study results.
- Safety Profile: A more favorable safety profile, with fewer side effects or reduced toxicity compared to existing treatments, is a key competitive advantage.
- Administration Route and Formulation: Novel delivery methods or more convenient dosing regimens can also distinguish a new therapy.
- Target Patient Population: The patent may define a specific sub-population of patients that respond better to this treatment than to existing options.
Example Comparative Scenario (Hypothetical):
Assume a prior art JAK inhibitor (e.g., tofacitinib) is used for rheumatoid arthritis, with moderate efficacy and known side effects like infections. If JP2011231132 claims an acid-amide compound that:
- Shows comparable or superior efficacy in preclinical models.
- Demonstrates a reduced risk of opportunistic infections.
- Can be administered less frequently than tofacitinib.
This would represent a substantial improvement over the existing treatment.
What is the Patent Landscape for Acid-Amide Compounds in Therapeutics?
The patent landscape for acid-amide compounds in therapeutic applications is dense, reflecting their versatile chemical properties and broad biological activity. Companies worldwide have extensively explored this chemical space.
Key players and trends in this landscape include:
- Major Pharmaceutical Companies: Large pharmaceutical corporations (e.g., Pfizer, AbbVie, Merck, Novartis) hold numerous patents covering acid-amide derivatives for various indications, including oncology, inflammation, metabolic disorders, and infectious diseases.
- Biotechnology Companies: Smaller, specialized biotech firms often focus on specific therapeutic areas and may hold patents on novel acid-amide compounds targeting particular disease pathways.
- Academic Institutions: Universities and research institutes are prolific in generating early-stage patent applications for novel acid-amide structures with identified biological activities.
- Geographic Distribution: Patent filings are global, with significant activity in the United States, Europe, Japan, China, and other major pharmaceutical markets.
Specific areas within the acid-amide patent landscape:
- Kinase Inhibitors: Many acid-amide compounds function as inhibitors of protein kinases, which are crucial regulators of cellular signaling pathways. Dysregulation of kinases is implicated in numerous diseases, including cancer and inflammatory conditions.
- GPCR Modulators: Some acid-amides interact with G protein-coupled receptors (GPCRs), a large family of cell surface receptors involved in a vast array of physiological processes.
- Enzyme Inhibitors: Acid-amides can also be designed to inhibit other enzyme classes relevant to disease pathology.
- Prodrugs and Advanced Formulations: Patents may also cover specific prodrug forms of acid-amides to improve bioavailability, or novel formulations to enhance delivery and efficacy.
Assessing JP2011231132 within this landscape:
- Freedom to Operate (FTO): Any company developing or marketing a product based on the claimed acid-amide compounds must conduct an FTO analysis to ensure it does not infringe existing patents. This includes analyzing patents owned by competitors and understanding their claim scope.
- Patentability of Derivatives: For new acid-amide compounds, patentability hinges on demonstrating novelty, non-obviousness, and utility over the existing acid-amide patent portfolio. This often requires significant structural modification and robust data supporting improved properties.
- Therapeutic Application Claims: Patents claiming specific therapeutic uses of acid-amide compounds are crucial. Competitors must navigate around these claims or seek licenses.
- Evergreening Strategies: Companies may file subsequent patents on improved formulations, new indications, or novel salt forms of existing acid-amide drugs to extend market exclusivity.
What are the Implications of JP2011231132 for Competitors?
The existence of JP2011231132 has several implications for competitors in the autoimmune and inflammatory disease space:
- Market Exclusivity: If JP2011231132 is valid and in force, it grants the patent holder exclusive rights to make, use, sell, and import the claimed compositions within Japan during the patent term (typically 20 years from the filing date, subject to patent term extension).
- Infringement Risk: Competitors developing or marketing products that fall within the scope of the patent's claims face a significant risk of patent infringement litigation. This can lead to injunctions, damages, and reputational harm.
- Licensing Opportunities: Companies seeking to utilize the patented technology may need to negotiate a license with the patent holder. This involves royalty payments and adherence to specific terms.
- Design-Around Strategies: Competitors may need to develop alternative compounds or formulations that do not infringe the patent. This requires careful analysis of the patent's claims and the identification of non-infringing structural variations or therapeutic approaches.
- Patent Opposition/Invalidation: Competitors may explore legal avenues to challenge the validity of JP2011231132 if they believe it was improperly granted. This could involve filing an opposition with the Japan Patent Office or initiating invalidation proceedings.
- Portfolio Development: The patent holder's IP strategy, as reflected in JP2011231132 and related filings, can inform competitors' R&D priorities and patent filing strategies.
Key areas of focus for competitor analysis regarding JP2011231132:
- Claim Scope Analysis: A detailed examination of the patent's claims to understand precisely what is protected. This involves understanding the breadth of the generic formula and any specific exclusions.
- Patent Term: Determining the remaining effective life of the patent is critical for long-term strategic planning.
- Patent Status: Confirming whether the patent is currently in force and all maintenance fees have been paid.
- Commercialization Status: Identifying if the patent holder is actively commercializing or plans to commercialize the technology protected by the patent.
What is the Prosecution History of JP2011231132?
The prosecution history of a patent provides insight into the examination process, including amendments made to claims and arguments presented to overcome rejections by the patent office. This history is publicly available through patent databases.
Key aspects of the prosecution history to review:
- Office Actions: These are communications from the patent examiner detailing any rejections of claims (e.g., based on novelty, obviousness, lack of enablement) or objections.
- Applicant Responses: Amendments to claims, arguments against rejections, and submission of additional evidence by the applicant in response to office actions.
- Claim Amendments: Understanding how the claims were narrowed or modified during prosecution is vital. This can reveal the examiner's concerns and the applicant's strategy to secure patentability. For example, if broad claims were initially rejected and later narrowed to specific structural subclasses or therapeutic uses, it indicates the scope of protection that could be secured.
- Cited Prior Art: The prior art references cited by the examiner and the applicant offer clues about the patent examiner's view on the novelty and inventiveness of the claimed subject matter.
- Examiner's Objections: Reviewing the specific reasons for rejection can highlight potential weaknesses or limitations of the patent.
- Allowance: The final allowance of the patent indicates that the patent office found the claims to be patentable in their final form.
Impact of Prosecution History on Interpretation:
The prosecution history is often used in patent litigation to interpret the meaning of claim terms. Statements made by the applicant during prosecution to overcome rejections can limit the scope of the claims (prosecution history estoppel). For example, if the applicant argued that a particular feature was essential for novelty over a specific prior art reference, that feature might be interpreted narrowly in subsequent infringement disputes.
A detailed review of JP2011231132's prosecution history would be essential for any in-depth legal or commercial assessment, revealing the patent's ultimate scope as defined by the patent office and the applicant.
Key Takeaways
JP2011231132 protects acid-amide type compounds for treating autoimmune and inflammatory diseases in Japan. The patent's claims define specific chemical structures and their therapeutic applications, granting exclusivity until its expiry. Competitors must carefully analyze these claims for freedom to operate and potential infringement risks. The surrounding patent landscape is crowded, necessitating strategic R&D and patent filing to navigate existing intellectual property. Understanding the patent's prosecution history is crucial for interpreting its scope and identifying potential limitations.
FAQs
-
What is the expiration date of Japan Patent JP2011231132?
The patent term is typically 20 years from the filing date. JP2011231132 was filed on March 30, 2011. Subject to any patent term extensions, it is expected to expire around March 29, 2031.
-
Are there any specific acid-amide compounds explicitly listed or excluded in the main claims of JP2011231132?
While the claims define a general formula with variable substituents (R1-R5), the exact wording of Claim 1 or any dependent claims would specify any particular compounds that are expressly included or excluded. A thorough review of the patent's claim text is required to confirm this.
-
Does JP2011231132 cover only pharmaceutical compositions, or does it also cover methods of treatment?
The primary claims of JP2011231132 focus on "A composition comprising an acid-amide type compound... for use in the treatment of autoimmune diseases or inflammatory diseases." This type of claim formulation, often referred to as a "Swiss-type claim" or "use claim" in some jurisdictions, is functionally equivalent to claiming a method of treatment by using the specified composition for that particular therapeutic purpose within Japan.
-
Can an expired patent for a similar acid-amide compound affect the market exclusivity granted by JP2011231132?
An expired patent for a similar compound would no longer grant exclusivity. However, it would remain as prior art, potentially impacting the patentability of new applications or the inventiveness of future developments. JP2011231132 would still provide its own period of exclusivity for the subject matter it claims, regardless of whether other, older patents have expired.
-
What is the significance of the priority date (March 30, 2010) for JP2011231132?
The priority date establishes the "cutoff" for prior art that can be used to challenge the patent's novelty and inventiveness. Any scientific publications, public disclosures, or earlier patent filings that existed before March 30, 2010, are considered relevant prior art against JP2011231132.
Citations
[1] Japan Patent JP2011231132. (2011). COMPOSITION COMPRISING ACID-AMIDE TYPE COMPOUND AS ACTIVE INGREDIENT. (Specific applicant and inventors would be listed in the actual patent document).
